Sunday, February 25, 2018 5:10:29 AM
CAR-T-Meso
Metastatic Pancreatic (Ductal) Adenocarcinoma
Epithelial Ovarian Cancer
Malignant Epithelial Pleural Mesothelioma
HTTPS://clinicaltrials.gov/ct2/show/NCT02159716
Even more to come
The latest exciting developments with CAR-T are still ringing in the ears of the industry and the good news is expected to keep coming. Novartis is far from done, with a slew of plans ready to unfold in the space, as Althoff outlined: “We are excited about the possibility of CAR-Ts to transform cancer care. Kymriah is just the first of Novartis' CAR-T cell therapies. The company also plans to file Kymriah with the FDA in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), as well as file applications with the European Medicines Agency for both B-cell ALL and DLBCL by the end of this year.
“As part of the company’ ongoing research and development collaboration with Penn, together we’ve generated CTL119 – a humanised anti-CD19 CAR – which is in initial clinical development for multiple B-cell malignancies,” he continued. “We’re also studying CART-BCMA, a novel, fully human CAR targeting BCMA, in multiple myeloma and CD123 CAR-T in myeloid leukaemia. Additionally we are studying a number of other CAR therapies in solid tumours, including a humanised anti-EGFRvIII CAR for Glioblastoma Multiforme, a lethal and common brain cancer, and a fully human anti-Mesothelin CAR (huCART-Meso) which recently began clinical testing.”
CAR-T Type Cancer indication Phase 1 Phase 2/ pivotal Phase 3 Submitted Approved
CD19 CAR-T Pediatric & young adult r/r ALL1 EU US
CD19 CAR-T r/r DLBCL2 US/EU
CD19 CAR-T DLBCL in 1st relapse2 Starting 2018
CD19 CAR-T r/r FL3 Starting 2018
CD19 CAR-T r/r DLBCL2
in combination
with pembrolizumab Starting 2018
CD19 CAR-T CLL4 Starting 2018
CAR-T-BCMA r/r Multiple Myeloma Starting 2018
CAR-T-EGFRvIII Recurrent GBM5 Started
CAR-T-Meso Advanced ovarian cancer,
Mesothelioma Started
Novartis has one of the most comprehensive CAR-T
development programs across multiple large indications
1. ALL – acute lymphoblastic leukemia 2. DLBCL – diffuse large B-cell lymphoma
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM